To create experimental systems that facilitate studies aimed at the responsiveness of hematopoietic progenitors to interleukin (IL)-6 in combination with IL-3, we introduced the human IL-6 receptor (hlL-6R) into the IL-Wependent cell line 32D. For this purpose, a retroviral vector containing the hlL-6R cDNA was constructed. 32D parental cells did not respond to IL-6, neither alone nor in combination with increasing concentrations of IL-3, and did not express detectable numbers of IL-6R as determined by 1251-lL-6 binding. 32D/ hlL-6R cells expressed high-affinity IL-6 binding and responded synergistically to IL-6 in combination with suboptimal amounts of IL-3 in DNA synthesis assays. In addition,
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To create experimental systems that facilitate studies aimed at the responsiveness of hematopoietic progenitors to interleukin (IL)-6 in combination with IL-3, we introduced the human IL-6 receptor (hlL-6R) into the IL-Wependent cell line 32D. For this purpose, a retroviral vector containing the hlL-6R cDNA was constructed. 32D parental cells did not respond to IL-6, neither alone nor in combination with increasing concentrations of IL-3, and did not express detectable numbers of IL-6R as determined by 1251-lL-6 binding. 32D/ hlL-6R cells expressed high-affinity IL-6 binding and responded synergistically to IL-6 in combination with suboptimal amounts of IL-3 in DNA synthesis assays. In addition, NE OF THE MULTIPLE activities attributed to 0 interleukin (1L)-6 is its stimulatory action on primitive hematopoietic IL-6 acts synergistically with IL-3 in supporting the formation of multilineage hematopoietic blast colonies in the colony-forming unit (CFU)-blast assay. 3 This assay probably identifies the most primitive hematopoietic cell population that can form colonies in semisolid in vitro culture? IL-6 hastens the appearance of the IL-3-induced blast colonies,1,2 and has been suggested to drive CFU-blast from the Go phase into the GI phase of the cell cycle. In the presence of suboptimal concentrations of IL-3 in culture, IL-6 has also been found to increase the numbers and size of the blast colonie~.~ Strikingly, the IL-6/IL-3 synergy is lost in the lineage-restricted progenitors, eg, CFU-granulocyte, monocyte (GM) and burstforming unit-erythroid (BFU-E) from adult bone m a r r~w .~ The effects of IL-6 on hematopoietic stem cells have been considered of potential clinical importance. It has been suggested that IL-6 can be applied to improve hematopoietic recovery, eg, in the context of bone marrow transplantation? A role for IL-6 has also been envisaged in the setting of retroviral-mediated gene transfer into hematopoietic stem cells, which requires that the target cells are stimulated to enter cell cycle before infection with the retroviral vector.6 Studies aimed at the mechanisms of action of IL-6 in immature hematopoietic cells are hampered by the scarcity of primitive cells among the highly heterogeneous marrow population.
The human IL-6 receptor (hILdR) has been molecularly cloned and some of its functional characteristics have been elucidated.' The IL-6R shares structural homology with a number of other hematopoietic growth factor receptors.8 IL-6 binds with high affinity to a complex formed by the IL-6R chain, which has no intracellular function itself, and to a 130-Kd glycoprotein (gp130), which is responsible for signal transducti~n.~J~
In the present study, we have investigated the IL-6 responsiveness of murine IL-3-dependent hematopoietic cell line 32D, before and after introduction of the hILdR by retroviral gene transfer. The 32D parental cells did not respond to IL-6, but on the expression of the hIL-6R in these cells, leading to the formation of high-affinity IL-6 binding sites, positive effects of IL-6 in combination with IL-3 on DNA synthesis and of IL-6 alone on cell survival were seen. Thus, following reconstitution of functional I L d R on their membranes, the 32D cells acquire IL-6 responsiveness. We conclude that murine factor-dependent hematopoietic cell lines with ectopic hIG6R may furnish attractive models for studies aimed at elucidating the intracellular events involved in IL-&mediated responses in primitive hematopoietic cells. (Beckman LS3800, Fullerton, CA). All data presented are the mean disintegrations per minute (dpm) 2 SD of triplicate cultures.
MATERIALS AND METHODS

Hematopoietic
A retroviral vector (XM6/Neo) was constructed for transduction of the hIL-6R in the murine hematopoietic cells (Fig 1) . XM6/Neo, a modification of the Moloney virus-derived N2 vector,14 is a nonsplicing vector that contains a multiple cloning region (BglII,ApaI, HindIII, XhoI) adjacent to the EcoRI site in N2 at approximately 1.5 kb, thus placing the inserted gene under the transcriptional control of the 5' long terminal repeat (LTR). The original neo resistance gene (Neo) in N2 has been replaced by the modified Herpes simplex thymidine kinase (Tk) promoter-driven Neo gene from pMClneo (Stratagene, La Jolla, CA). A full-length cDNA encoding the hIG6R, recovered from pBSF2R.236: was inserted into this vector (Fig 1) . To obtain ecotropic psi-2 virus-packaging cell clones that produce recombinant virus in high titers, pXM6/hIL-6R/Neo was first transfected into amphotropic packaging (PA317) cells by cationic liposomemediated transfection (Lipofectin reagent, BRL Life Technologies, Bethesda, MD) in Optimem-I medium (GIBCO, Paisley, Scotland).1s After a 17-hour incubation, this medium was changed for RPMI-1640 with 10% FCS. Another 48 hours later, culture medium containing the recombinant virus transiently produced by the PA317 cells was harvested, passed through a 0.45-pm filter, and added to semiconfluent psi-2 cultures (in T25 culture flasks) in the presence of polybrene (6 kg/mL). After 16 hours, the medium was replaced by fresh medium (10 mL) and, another 48 hours later, selection on G418 (GIBCO, 1 mg/mL) was initiated. A clone that produced virus in titers between 105 and 106 infective particles per milliliter culture medium, as estimated in an NIH-3T3 infection assay, was selected for further use. Growth factor-dependent hematopoietic cells were infected by adding 0.45 pm filtered virus containing supernatant (30% vol/vol) and polybrene to the cultures during overnight incubation. Cells were then washed twice with phosphate-buffered saline (PBS) and subsequently cultured in 24-well dishes (Greiner) in fresh growth factor<ontaining medium. After 48 hours, G418 (1 mg/mL) was added to the cultures. Two to 3 weeks later, G418-resistant cells were harvested from individual culture wells and placed in methylcellulose-containing cultures, and single colonies picked and expanded in liquid culture to obtain clones.
Flow cytomehic analysis of hIL-6R expression.
To analyze the expression of hIL-6R on the murine hematopoietic cells after retroviral gene transfer, 0.5 x 106 cells were treated with the anti-hIL-6R monoclonal antibody (MoAb) MT18I6 and goat antimouse immunoglobulin coupled to fluorescein isothiocyanate (GAM/FITC, Nordic, Tilburg, The Netherlands) using established procedures.17 To determine background fluorescence, cells were also treated with GAM/FITC alone. Flow cytometry was performed using a FACS 440 (Becton-Dickinson, Mountain View, CA) as described.I7 Pure hIL-6 was labeled with lZI using the Bolton-Hunter method as described.I8 To estimate receptor number and affinity for the ligand, cells (2 to 5 x 106) were incubated for 1 hour at 37°C in 100 kL at serial dilutions of the radiolabeled ligand. To determine nonspecific binding of the radioactivity, incubations in the presence Retroviral gene transfer.
Radiowdination of growth factors and binding experiments.
of excess (50 nmol/L) nonlabeled growth factor were performed in parallel.
RESULTS
Introduction and expression of hIL-6R in murine factordependent cell lines. 32D, CTLL, and T1165 cell lines were incubated with the psi-2-derived XM6/hIL-BR/Neo virus and infected clones were selected on the basis of G418 resistance. The presence of hIL-6R on the selected clones could be demonstrated with the MoAb MT18 by indirect immunofluorescence and flow cytometry (results not shown). No specific binding of MT18 to the parental cells was observed. By performing Scatchard analysis, we then determined the capacities of 32D, CTLL, and T1165 cells, before and after introduction of hIG6R, to bind *=I-hIL-6. Specific IL-6 binding to the 32D and CTLL parental cells was not observed (Table 1) . lZ1-hIG6 binding to the T1165 cells appeared too low for estimation of receptor number and affinity (Table l), suggesting that these IL-&responsive cells must express IL-6 receptors at a very low average density. As shown in Fig 2 and Table 1 , 32D/hIL6R, CTLL/hIL-6R, and T1165/hIL-6R cells express highaffinity IL-6 binding sites at estimated densities varying from 273 to 6,074 per cell.
Prolferatwn-inducing effects of IL-6 on parental and hIL-6R-apressing T1165, 320, and CTLL cells in DNA synthesis assay. We first compared the proliferative responses of the IL-Uependent T1165 with those of the T1165/hIL-6R cells to increasing concentrations of hIL-6. This experiment was performed to establish whether the retrovirally introduced hIL-6R can participate in the transduction of a mitogenic signal in mouse cells, presumably through dimerization with the murine GP130 analogue. The T1165 cells maintained in our laboratory require a relatively high concentration (3,000 U/mL) of hIL-6 for optimal growth, due to the low numbers of IL-6R (<50) on the cells. In contrast, maximal proliferation of T1165/hIL-6R cells (estimated IL-6 receptor density, 6,000 sites/cell) occurred at a concentration of 100 U/mL hIG6 (Fig 3) . Thus, the T1165/hIL-6R cells showed a 30-fold higher sensitivity to hIL-6 than the parental T1165 cell line. These results confirm that ectopic hIL-6R are functional in murine cells.
Subsequently, the mitogenic effects of hIL-6 on 32D parental cells, 32D cells infected with control retroviral vector (32D/XM6 Neo), and 32D/hIL-6R cells were investigated. 32D and 32D/XM6 Neo cells (expressing no detectable IL-6 binding sites) did not show any responsiveness to hIL-6 (3,000 U/mL), neither alone nor when added in combination with increasing concentrations of purified mIL-3 ( Table 2 , Fig 4) . 32D/hIL-6R cells, on the other hand, generally responded weakly to hIL-6 alone ( Table 2 ). The synergistic effect of hIL-6 on the 32D/hIL-6R cells became evident in the presence of 0.1 to 1.0 U mIL3/mL, depending on the clone analyzed. An IL-6 titration experiment with 32D/hIL-6R clone 3 cells showed that 3,000 U/mL of hIL-6 optimally synergized with mIL-3 (1 U/mL) (Fig 5) . Two other independent 32D/hIL-6R isolates (clones 1 and 2) exhibited IL-6 responses similar to those shown in Fig 4, indicating that IL-6/IL-3 synergy is a consistent characteristic of 32D/hIL-6R cells (Table 2 ). In two subclones of 32D/hIL-6R clone 1, ie, subclones 1,l and lJ6, hIL-6 synergized with mIL-3, whereas hIL-6 alone did not provoke a mitogenic response (Table 2 ). In another subclone (1,18), on the other hand, a significant response to IL-6 alone was observed (Table 2) . These data are indicative of some intraclonal variability, independent on the site of viral integration. hILdR introduced into a murine factor-dependent hematopoietic cell line cannot always mediate proliferative responses. For instance, the rate of DNA synthesis in two independent clones of the IL-2-dependent T-cell line CTLL expressing hILdR (CTLL/hIL-6R) did not increase, neither in response to IL-6 alone nor in combination with increasing amounts of hIL-2. A representative example of this analysis is shown in Fig 6. Prolifeation and survival of 32DlhlL-6R cells in suspension culture. To evaluate the capacity of hIL-6 to support cell production and survival, 32D/hIL-6R cells were incubated at a start concentration of 5 x lo4 cells/mL and cultured with and without hIL-6 (3,000 U/mL). IL-6 alone did not promote the production of 32D/hIL-6R cells after culture for several days. In the presence of a suboptimal concentration (0.1 U/mL) of mIL-3, the addition of hIL-6 to these cultures resulted in an approximately twofold increase of the viable cell yield after 4 days of culture. In an optimal concentration of mIL-3, ie, 3 U/mL, the cells had multiplied more than 10-fold. Thus, the synergistic effect of hIL-6 with 0.1 U/mL mIL-3 was evident in continued suspension culture, although less pronounced as compared with the DNA synthesis assay. To investigate a possible short-term effect of hIL-6 on the survival of 32D/hIL-6R cells in the absence of mIL-3, we performed experiments with 32D/hIL-6R (clone 3) cells and parental 32D control cells that had been first washed extensively to remove residual mIL-3. These cell samples were then split into three portions; one sample was cultured with hIL-6 (3,000 U/mL), one with mIL-3 (10 U/mL), and the third without factor. At various time intervals, viability of cells was assessed by trypan blue exclusion and cells were further cultured in 3H-TdR uptake assays in the presence of 10 U/mL mIL-3, to determine survival of mIL-3-responsive clonogenic cells. IL-6 significantly delayed the decrease in percentage of viable 32D/hIL-6R cells observed in the absence of growth factor (Fig 7) . This effect of IL-6 was not seen on the 32D parental cells (Fig 7) . Finally, the effects of hIL-6 on the survival of IL-3-responsive 32D/hIL-6R cells (clone 3) are shown in Fig 8. Cells precultured in hIL-6-containing medium for 6 to 24 hours showed a significantly higher mIL-3 responsiveness after incubation in DNA synthesis assays than the cells precultured in the absence of hIL-6. The IL-&independent increase in IL-3 responsiveness observed between 6 and 18 hrs of culture most likely results from cells that had already been activated by mIL-3 before withdrawal of mIL-3 at the initiation of the experiment. Again, no such effects of hIL-6 were seen with the parental 32D cells. After 72 hours of culture, this hIL-6-mediated support of the survival of proliferation competent 32D/hIL-6R cells was no longer evident.
DISCUSSION
The hematopoietic colony-forming cells represent a minute fraction, ie, less than 0.1%, of the heterogeneous bone marrow cell population. This prohibits studies aimed at the analysis of the mechanisms by which IL-6 exerts its effects on the multilineage progenitors and of how IL-6 responsiveness is lost during commitment. In an attempt to obtain insight in at least some of these aspects, we studied WTdR uptake was assessed 3 days after addition of growth factors. 'Mean dpm f SD of triplicate cultures.
the action of IL-6 in the murine IL-3-dependent immature myeloid cell line 32D, before and after the introduction and stable expression of the hIL-6R. For this purpose, a retroviral vector containing the hIL-6R cDNA was constructed. High-affinity binding of lZI-hIL-6 to the 32D/ hIL-6R cells was observed. The 32D/hIL-6R cells acquired a (synergistic) responsiveness to IL-6 in DNA synthesis assays. The parental 32D cells lacked ILdR and were IL-6-nonresponsive according to the same criteria of measurement. The data show that the inability of these IL-3-dependent myeloid progenitor cells to respond to IL-6 is due to a lack of IL-6R, and that intracellular properties do not prohibit the transduction of signals provided by IL-6. This may indicate that the lack of IL-6 responsiveness in myeloid progenitors results from the disappearance of functional IL-6 binding sites at an early stage in myeloid cell development, rather than from shutting off the intracellular IL-6 signaling pathway. All 32D/hIL-6R (sub)clones responded to IL-6 in synergy with IL-3 in DNA synthesis assays. On the other hand, the response to IL-6 alone showed some variation, even among different subclones of one original infectant (Table 2 ). Although we have not yet studied this phenomenon in detail, we assume that it may reflect intraclonal cellular heterogeneity of the 32D cell line. 19 To compare the observed function of the hILdR in the IL-3-dependent cell lines with other factor-dependent cells, we have investigated the function of hILdR introduced into IL-6-dependent plasmacytoma cells T1165 and IL-Zdependent T-cells CTLL. T1165/hIL-6R cells ex- pressed high numbers of IL-6 binding sites as compared with the parental cells, on which IL-6R were hardly detectable in IL-6 binding experiments (Table 1 ). In addition, T1165/hIL-6R cells showed a 30-fold increase in sensitivity to IL-6 in the 3H-TdR uptake assay over the T1165 parental cells. These data confirmed that the retrovirally introduced hIL-6R could participate in the formation of a functional receptor complex capable of transducing a full mitogenic signal, provided that the appropriate intracellular machinery is available. In contrast, in CTLL/hIL-6R cells, despite the fact that these cells expressed significant numbers of high-affinity IL-6 binding sites (Table l) , no stimulative effects of IL-6, alone or with increasing amounts of IL-2, were seen in the 3H-TdR uptake assay.
hIL-6R chains themselves have a low affinity for IL-6 and lack the ability to transduce signals into cells. To form a functional high-affinity receptor in B cells and hepatoma cells, hIL-6R has to dimerize with a membrane glycoprotein, gp130, that acts as signal t r a n s d u~e r .~J~ It has already been reported that hIL-6R can associate with murine gp130 and form a functional receptor complex in a mouse B-lymphoma cell line.*O In immunoprecipitation experiments using the MT18 MoAb with 32D/hIL-6R cells, metabolically labeled with 35S-methionine and lysed with the digito- nin lysis buffer according to Taga et a1,9 we could coprecipitate a protein of approximately 130 Kd, presumably the mouse gp130 (data not shown). Thus, it appears most likely that gp130 is also involved in transducing the IL-6 signal in hematopoietic cells.
Our studies have shown that IL-6 promotes the survival of 32D/hIL-6R cells in short-term incubation assays (Figs 7 and 8), most likely by delaying programmed cell death or apoptosis.20 This short-term effect of IL-6 might at least in part explain the observed synergy between IL-6 and suboptimal amounts of IL-3 in the DNA synthesis assay. Evidence that IL-6 can delay apoptosis in hematopoietic cells has recently been obtained using the murine leukemia cell line M1 after introduction of a cDNA encoding the p53 protein.21 Expression of the wild-type p53 in the M1 cells resulted in rapid cell death, which could be counteracted by IL-6 through a presently unknown mechanism. We have not yet investigated whether p53 is involved in apoptosis after growth factor deprivation of 32D cells. Although it remains to be established whether the observations made in the (.) at an optimal concentration of mlL-3 (0) and with hlL-6 (3,000 U/mL) (+) . Viability of cells (n = 400) was determined by trypan-blue exclusion. Ml/p53 and 32D/hIL-6R models can be extended to normal hematopoietic progenitors, a role of IL-6 in promoting the survival of primitive hematopoietic precursors, possibly by antagonizing the activity of p53, may be anticipated.
It is not yet clear how the effects of IL-6 on 32D/hIL-6R cells relate to the activity of IL-6 in the blast colony assay. Since IL-6 hastens the formation of blast colonies in vitro, it has been suggested that IL-6 activates stem cells residing in Go to enter the G I phase of the cell cycle.1,2 We could not establish whether IL-6 exerts such an effect on the 32D/ hILdR cells, because we were unable to force these cells into Go. Even after prolonged growth factor deprivation, ie, when a significant proportion of cells had already become apoptotic, Northern blot analysis still showed the presence of c-myc and c-fos transcripts in the remaining living cells, indicating that, despite their starvation, cells were still in cycle.22 A second described effect of IL-6 on CFU-blast is that IL-6 increases the number and size of blast colonies in the presence of suboptimal concentrations of IL-3.4 This observation has raised the suggestion that IL-6 can upregulate the numbers of I L 3 R on the blast colony-forming cells. Incubation of the 32D/hIL-6R cells with hIL-6 followed by lzI-mIL-3 binding analysis did not provide evidence for the ability of IL-6 to upregulate I L 3 R on these cells (data not shown).
It remains at present unknown whether IL-6 is able to activate genes that control replication of 32D/hIL-6R cells. hIL-6 did not upregulate the expression of c-myc and c-fos in 32D/hIL-6R clone 3 cells (data not shown). These genes are transcribed within minutes after stimulation of growth factor-dependent hematopoietic cell lines with mIL-3.22 Cortese et al have identified the IL-6-responsive elements (IL-6REs) present in the promoter region of acute-phase genes expressed in liver cells, as well as the nuclear protein (IMDBP) that transactivates I L -~R E S .~~" To study the possibility that IL-6RE are involved in IL-&mediated responses of hematopoietic precursors, we are currently investigating whether IL-6RE can be activated by IL-6 in 32D/hIL-6R cells using the CAT-reporter gene assay.
Factor-dependent murine hematopoietic cells expressing ectopic hILdR provide convenient models for future studies aimed at the intracellular events involved in IL-6-mediated responses in primitive hematopoietic cells. Particularly, these models may help to elucidate the steps in signal transduction that determine the differential action of growth factors and synergistic factors in the early stages of hematopoiesis.
